Nov 29, 2023 / 03:30PM GMT
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Hi, everybody, thanks for joining us. Matt O'Brien, I cover Med-Tech here at Piper. Very excited to have the Tandem Diabetes management team here with us. From the company, we've got John, who's the CEO, and then Susan, who's the Head of IR and Corporate Communications. Leigh can't be here because of a family issue, unfortunately, which is much more important than talking to Matthew O'Brien. I can assure you of that. But thank you, so much for coming. I do appreciate it.
John F. Sheridan - Tandem Diabetes Care, Inc. - President, CEO & Director
Yes.
Questions and Answers:
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research AnalystI guess -- so sick of talking about these GLPs, but let's start with that, first of all. Type 1 penetration, about 40% today.
John F. Sheridan - Tandem Diabetes Care, Inc. -
Trustpilot
